Business Context and Reporting Period
Company: Inmune Bio, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: August 16, 2023
Reporting Period: Single event date (August 16, 2023)
The Company is an emerging growth company incorporated in Nevada with principal executive offices in Boca Raton, Florida. This filing reports the entry into a material definitive agreement regarding its capital raising capabilities.
Key Financial Metrics
This Form 8-K does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity metrics. The filing focuses exclusively on a corporate action regarding a sales agreement.
Material Changes and Corporate Actions
Amendment to At-The-Market (ATM) Sales Agreement:
- Counterparty: BTIG, LLC.
- Original Agreement: Entered on March 10, 2021, allowing the sale of common stock up to an aggregate offering price of $45,000,000.
- Amendment No. 1 (August 16, 2023): Modified the Sales Agreement to specify that future offers and sales of Common Stock will be made through a prospectus supplement to the Company's shelf registration statement on Form S-3 (File No. 333-254221), declared effective on May 5, 2021.
- Execution: The Company filed a prospectus supplement dated August 16, 2023, with the SEC.
Sales Methodology: Shares may be sold via "at the market offerings" as defined in Rule 415(a)(4), including sales through The Nasdaq Capital Market, market makers, or negotiated transactions. BTIG acts as a sales agent and is not obligated to purchase shares on a principal basis.
Guidance, Outlook, and Risks
Management Commentary: The Company is not obligated to make any sales of Common Stock under the Sales Agreement. Any determination to sell shares will depend on market conditions and the Company's capital raising needs.
Risks and Contingencies: The filing includes standard disclaimers stating that the report does not constitute an offer to sell or a solicitation of offers to buy securities in any jurisdiction where such offer would be unlawful prior to registration or qualification.
Investor Verification Checklist
- Verify the status of the shelf registration statement (Form S-3, File No. 333-254221) to ensure it remains effective for future sales.
- Review the full text of Amendment No. 1 to the Sales Agreement (Exhibit 1.1) for specific terms regarding price, time, or size limits.
- Monitor subsequent filings for actual sales activity under the amended ATM program to assess dilution impact.
- Confirm the Company's current cash position and capital needs in the most recent 10-Q or 10-K, as this filing does not provide liquidity data.